CCCC: C4 Therapeutics Inc Price-to-Revenue Multiple

Symbol and logo of brand C4 Therapeutics Inc (CCCC)

C4 Therapeutics, Inc. (CCCC) develops innovative cancer therapies via the TORPEDO platform, which eliminates hazardous proteins. The ratio of value to sales volume demonstrates the asset's valuation dynamics, where the 11.20 level reflects the current magnitude. Capital is supported by advances from global pharma behemoths, yet the absence of market sales and high R&D expenditures create risks that necessitate strict management control.

CCCC C4 Therapeutics Corp Market Cap to Revenue (07/04/2022 - 11/14/2026)

Analytical breakdowns for C4 Tx (CCCC)

- share price and consensus valuation forecast:
Price Performance Chart c4therapeutics.com|CCCC - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization C4 Tx|CCCC - Enterprise Value
- book capitalization data:
Net Asset Value per Share C4 Therapeutics|CCCC - Company Net Assets|Market Cap to Book Value Multiple c4therapeutics.com|CCCC - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital C4 Therapeutics, Inc.|CCCC - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio C4 Therapeutics Corp|CCCC - Company Total Debt|Debt to Net Assets Ratio C4 Tx|CCCC - Company Long-Term Liabilities|Amount of Current Liabilities C4 Therapeutics|Intermediate Coverage Ratio c4therapeutics.com
- earnings and multiples data:
CCCC - Net Profit|Expected Net Profit C4 Therapeutics, Inc.|CCCC - Price to Earnings Ratio|Future Price to Earnings Multiple C4 Therapeutics Inc|CCCC - PEG Multiple|EV/EBITDA Multiple C4 Tx|CCCC - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months C4 Therapeutics|CCCC - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months c4therapeutics.com|CCCC - Earnings growth in current year|Expected earnings per share growth for next year C4 Therapeutics, Inc.
- sales revenue and business income indicators:
CCCC - Company Sales Volume|Company Future Sales Volume c4therapeutics.com|CCCC - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple C4 Tx
Summary company analytics:c4therapeutics.com, CCCC
Mass-produced product of c4therapeutics.com

The integration of ESG principles and the ethical development of oncology drugs at C4 Therapeutics, Inc. (CCCC) influence its investment attractiveness, which is reflected in the P/S ratio calculated by dividing market capitalization by annual sales volume. Analyzing this ratio of capitalization to revenue determines whether the business valuation is justified by its operational successes or if the market is pricing in a discount due to fundamental risks, warning the investor of a potential capital freeze.

Who C4 Therapeutics, Inc. competes with

GMAB (genmab.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EXEL (Exelixis)|Price-to-Revenue Multiple Nuvalent Inc|Kymera Therapeutics Inc - P/S Multiple|Price to Sales IDEAYA Corp|ELVN (Enliven Therapeutics) - Market Cap to Revenue|ORIC: Market Cap to Sales Volume|RLAY (Relay Therapeutics, Inc.) - P/S Multiple|Price to Sales Nurix Therapeutics Inc NRIX|P/S Multiple TYRA|Verastem Corp - Market Cap to Revenue Ratio|Monte Rosa Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CGEM|IMRX: Market Cap to Revenue|Black Diamond Therapeutics, Inc. - Market Cap to Sales Volume|RPTX: P/S Multiple|PMV Pharmaceuticals, Inc - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales Propanc Biopharma, Inc. PPCB|Price-to-Revenue Ratio Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics, Inc.)|P/S Multiple Blueprint Medicines Corp. BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX